We assign a fundamental rating of 3 out of 10 to NGNE. NGNE was compared to 525 industry peers in the Biotechnology industry. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability. NGNE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year NGNE has reported negative net income.
In the past year NGNE has reported a negative cash flow from operations.
NGNE had negative earnings in each of the past 5 years.
In the past 5 years NGNE always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of NGNE (-26.11%) is better than 70.48% of its industry peers.
NGNE has a Return On Equity of -28.30%. This is in the better half of the industry: NGNE outperforms 77.52% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.11%
ROE	-28.3%
ROIC	N/A

ROA(3y)-29.45%

ROA(5y)-28.26%

ROE(3y)-34.92%

ROE(5y)-32.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NGNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NGNE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NGNE has more shares outstanding
The debt/assets ratio for NGNE has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 6.45 indicates that NGNE is not in any danger for bankruptcy at the moment.
NGNE has a better Altman-Z score (6.45) than 76.19% of its industry peers.
NGNE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
NGNE has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: NGNE outperforms 52.95% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.45

ROIC/WACCN/A

WACC8.88%

2.3 Liquidity

NGNE has a Current Ratio of 18.39. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 18.39, NGNE belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
NGNE has a Quick Ratio of 18.39. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 18.39, NGNE belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	18.39
Quick Ratio	18.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.20% over the past year.

EPS 1Y (TTM)14.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.81%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NGNE will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.73% on average per year.
NGNE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 131.75% yearly.

EPS Next Y-0.23%

EPS Next 2Y-11.54%

EPS Next 3Y-12.73%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y131.75%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.